VAHEBIO — Science · Longevity · Optimised
The Compendium

Weight Management

Retatrutide

Triple GIP/GLP-1/glucagon agonist in late-stage trials showing unprecedented weight loss.

Half-life
~6 days
Route
Subcutaneous, once weekly

Overview

Retatrutide is an investigational Eli Lilly peptide that simultaneously activates GIP, GLP-1 and glucagon receptors. Not yet approved by any regulator.

Mechanism of action

Adds glucagon-receptor agonism to the incretin backbone, increasing energy expenditure and lipolysis in addition to appetite suppression and insulin sensitisation.

Evidence base

Phase 2 (NEJM, 2023) reported 24.2% mean body-weight reduction at 48 weeks on 12 mg weekly. Phase 3 TRIUMPH programme ongoing.

Typical dosing

Trial regimens escalated from 2 mg to 4, 8 or 12 mg weekly. Open the dose calculator →

Safety & contraindications

GI adverse effects similar to other incretin therapies. Transient heart-rate increase observed at higher doses; long-term safety unestablished.

Related peptides

Semaglutide
Same class
Weight Management
Tirzepatide
Same class
Weight Management
AOD-9604
Same class
Weight Management
Adipotide
Same class
Weight Management

Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.